TD Private Client Wealth LLC Grows Stock Position in Gilead Sciences, Inc. $GILD

TD Private Client Wealth LLC lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 46.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 65,256 shares of the biopharmaceutical company’s stock after acquiring an additional 20,600 shares during the period. TD Private Client Wealth LLC’s holdings in Gilead Sciences were worth $7,243,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently added to or reduced their stakes in the company. GoalVest Advisory LLC boosted its stake in Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares during the last quarter. Corundum Trust Company INC acquired a new stake in shares of Gilead Sciences in the third quarter valued at about $26,000. Harbor Asset Planning Inc. acquired a new position in Gilead Sciences during the second quarter worth about $27,000. Howard Hughes Medical Institute acquired a new position in Gilead Sciences during the second quarter worth about $30,000. Finally, Putney Financial Group LLC grew its stake in Gilead Sciences by 53.4% during the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 94 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction that occurred on Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the completion of the transaction, the chief executive officer owned 581,203 shares of the company’s stock, valued at approximately $69,389,826.17. This trade represents a 1.69% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $125.86, for a total transaction of $3,524,080.00. Following the completion of the sale, the insider owned 107,193 shares of the company’s stock, valued at $13,491,310.98. This trade represents a 20.71% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 136,257 shares of company stock worth $16,855,192. 0.27% of the stock is owned by company insiders.

Analysts Set New Price Targets

GILD has been the topic of several recent research reports. BMO Capital Markets set a $135.00 target price on Gilead Sciences in a report on Tuesday, November 25th. Morgan Stanley boosted their price objective on Gilead Sciences from $147.00 to $151.00 and gave the stock an “overweight” rating in a research note on Friday, December 12th. Wall Street Zen upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 3rd. Wolfe Research reiterated an “outperform” rating and set a $150.00 price target on shares of Gilead Sciences in a report on Monday, December 15th. Finally, Needham & Company LLC boosted their price target on shares of Gilead Sciences from $133.00 to $140.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $133.20.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $122.60 on Tuesday. The firm has a market cap of $152.11 billion, a PE ratio of 19.01, a price-to-earnings-growth ratio of 0.64 and a beta of 0.33. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. Gilead Sciences, Inc. has a 52 week low of $89.02 and a 52 week high of $128.70. The business’s fifty day simple moving average is $123.28 and its 200-day simple moving average is $117.77.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The firm had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. During the same period last year, the company earned $2.02 EPS. The company’s quarterly revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th were paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date of this dividend was Monday, December 15th. Gilead Sciences’s payout ratio is 48.99%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.